Why ASDN Could Massively Outperform IONS in 2019
Earlier this week, there was a news that Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.
Novartis will do a Phase 3 trial of TQJ230, also known as AKCEA-APO(a)-LRx, against an inherited form of cardiovascular disease where people have elevated levels of so-called lipoprotein (a) that cannot effectively be cut via diet and lifestyle changes and plays a role in the narrowing of the arteries, heart attacks, thrombosis and stroke.
The stock made 52-week high of $72.20 in yesterday’s session and are up almost 80% from its 52-week low of $39.07.
]]>